List of Excipients in Branded Drug RUGBY ALL DAY RELIEF

Generic Drugs Containing RUGBY ALL DAY RELIEF

Company	Ingredient	NDC	Excipient
Rugby Laboratories	naproxen sodium	0536-1093	CELLULOSE, MICROCRYSTALLINE
Rugby Laboratories	naproxen sodium	0536-1093	FD&C BLUE NO. 2 ALUMINUM LAKE
Rugby Laboratories	naproxen sodium	0536-1093	HYPROMELLOSE
Rugby Laboratories	naproxen sodium	0536-1093	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in RUGBY ALL DAY RELIEF?

# Of NDCs	Excipient
4	CELLULOSE, MICROCRYSTALLINE
1	CI 77891
2	FD&C BLUE NO. 2 ALUMINUM LAKE
2	FD&C BLUE NO. 2--ALUMINUM LAKE

Rugby All Day Relief Excipient Strategy and Commercial Opportunities

Last updated: August 29, 2026

Rugby All Day Relief is an OTC naproxen sodium product, typically supplied as 220 mg tablets or caplets for temporary relief of minor arthritis, muscle aches, backache, headache, toothache, menstrual cramps, and fever. Its commercial position depends on low-cost manufacturing, acceptable tablet performance, packaging efficiency, and differentiation through dosage form rather than active-ingredient exclusivity.

Naproxen sodium is an established, nonprescription active ingredient. The product has no meaningful composition-of-matter patent barrier, no biologic exclusivity issue, and generally no Orange Book-listed patent strategy comparable with branded prescription products. The main opportunities are private-label expansion, improved swallowability, rapid-disintegration formats, smaller package counts, and channel-specific packaging.

What active ingredient and dosage form does Rugby All Day Relief use?

Rugby All Day Relief is generally marketed with naproxen sodium 220 mg as the active ingredient. Each 220 mg naproxen sodium tablet is equivalent to approximately 200 mg naproxen.

The standard OTC labeling supports use in adults and children 12 years and older. Typical directions permit one tablet every 8 to 12 hours, with a maximum of three tablets in 24 hours unless directed by a physician. The product is positioned as an extended-duration OTC pain reliever because naproxen sodium provides longer dosing intervals than many immediate-release acetaminophen or ibuprofen products.[1]

Attribute	Rugby All Day Relief
Active ingredient	Naproxen sodium
Common strength	220 mg
Therapeutic category	OTC analgesic, antipyretic, nonsteroidal anti-inflammatory drug
Typical users	Adults and children 12 years and older
Typical dosing interval	Every 8 to 12 hours
Maximum OTC daily dose	660 mg in 24 hours
Reference-brand comparison	Aleve 220 mg
Regulatory pathway	OTC monograph or monograph-aligned private-label product
Biosimilar relevance	None
Core commercial model	Generic and store-brand substitution

The exact excipient composition depends on the product’s National Drug Code, manufacturer, tablet coating, and package configuration. A commercial review should distinguish the specific Rugby SKU from similarly named products sold through institutional, retail, or private-label channels.

What excipients are likely to be used in Rugby All Day Relief?

The excipient system for a naproxen sodium tablet normally has five functional objectives:

1. Provide adequate powder flow and content uniformity.
2. Produce sufficient tablet hardness for packaging and transport.
3. Permit rapid disintegration and dissolution.
4. Mask the drug’s taste and improve swallowability.
5. Protect the tablet from moisture, light, and mechanical damage.

A conventional formulation may use a diluent such as microcrystalline cellulose, lactose, starch, or dibasic calcium phosphate. A superdisintegrant such as croscarmellose sodium, crospovidone, or sodium starch glycolate can support rapid breakup after ingestion. Povidone or a comparable binder can improve granule integrity. Magnesium stearate, stearic acid, or another lubricant reduces sticking and ejection force during compression.

Film-coating systems may contain hypromellose, polyethylene glycol, titanium dioxide, talc, and colorants. Colloidal silicon dioxide can improve flow and reduce formulation variability. Sodium lauryl sulfate or another wetting agent may assist dissolution where the formulation requires improved surface wetting.

Excipient function	Candidate materials	Commercial purpose
Dilution and compressibility	Microcrystalline cellulose, lactose, starch, calcium phosphate	Controls tablet weight and compression behavior
Disintegration	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid tablet breakup
Binding	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves mechanical strength
Lubrication	Magnesium stearate, stearic acid, sodium stearyl fumarate	Reduces sticking and ejection force
Flow improvement	Colloidal silicon dioxide	Improves hopper flow and blend uniformity
Wetting	Sodium lauryl sulfate, poloxamers	Can improve dissolution and wetting
Coating	Hypromellose, polyethylene glycol, talc, titanium dioxide	Improves appearance, handling, and swallowability
Color	Approved iron oxides or synthetic colorants	Product identification and branding

The preferred strategy is usually a robust, low-cost direct-compression or dry-granulation platform. Wet granulation may improve content uniformity and tablet strength but introduces greater processing cost, moisture exposure, and scale-up complexity.

How should the excipient strategy address naproxen sodium performance?

Naproxen sodium is more water-soluble than naproxen, but dissolution still depends on particle size, wetting, tablet porosity, lubricant concentration, and compression force. Excessive hydrophobic lubrication can slow tablet disintegration and dissolution. The formulation should therefore control lubricant blending time and concentration.

A practical development target is a tablet that balances:

• rapid disintegration without excessive friability;
• sufficient hardness for bottling and blister packaging;
• consistent dissolution across commercial-scale lots;
• low tablet weight for easier swallowing;
• stable performance under elevated temperature and humidity;
• compatibility with high-speed compression equipment.

Naproxen sodium can also create taste and mouthfeel concerns if the tablet is chewed or begins to disperse in the mouth. A film coat can improve patient acceptance. For a caplet, shape and surface smoothness may create greater commercial value than a more complex excipient system.

Excipient selection should comply with FDA inactive-ingredient precedents, compendial standards, and applicable current good manufacturing practice requirements. FDA’s Inactive Ingredient Database can support route- and dosage-form-specific precedent review, but it does not replace product-specific compatibility, stability, and performance testing.[2]

What formulations are protected or commercially differentiable?

The conventional immediate-release naproxen sodium tablet has limited patent-based differentiation. Commercial differentiation is more likely to arise from formulation execution, packaging, and consumer positioning.

Potential product extensions include:

Easy-swallow caplets

A thin, oval, film-coated caplet can improve swallowing and reduce tablet breakage. The opportunity is strongest in 50-count, 100-count, and club-store packages where consumers compare physical usability across private-label products.

Rapid-disintegrating tablets

A fast-disintegrating format could support consumer claims relating to tablet breakup, subject to substantiation and OTC labeling restrictions. The formulation would require careful control of friability, moisture sensitivity, taste, and packaging.

Liquid-filled capsules

A liquid-filled naproxen sodium capsule could offer a premium dosage form with improved visual differentiation. It would carry higher manufacturing and packaging costs, greater leak-risk controls, and more demanding stability requirements.

Blister-pack products

Unit-dose blister packaging supports travel, controlled use, and institutional dispensing. It also reduces child-access exposure only where the package is designed and tested as child-resistant or unit-dose compliant under applicable requirements.

Lower-count and condition-specific packs

Retailers can target menstrual pain, back pain, travel, sports, or workplace use through package architecture. Claims must remain within the permitted OTC labeling framework and avoid unsupported disease-treatment language.

Combination products

A naproxen sodium combination product could create a new commercial segment, but it would face substantially greater regulatory and safety complexity. Combinations with other analgesics, decongestants, or gastrointestinal products require careful review of monograph eligibility, labeling, duplicate-ingredient warnings, and clinical rationale.

What is the FDA regulatory status of Rugby All Day Relief?

Naproxen sodium oral analgesic products fall within the FDA’s OTC internal analgesic framework. FDA regulations establish permitted active ingredients, indications, warnings, directions, and labeling conditions for OTC analgesics.[3]

The primary regulatory risks are not patent related. They are:

• failure to conform to the applicable OTC monograph framework;
• incorrect strength or dosing directions;
• inadequate NSAID warnings;
• failure to address gastrointestinal bleeding, cardiovascular, renal, pregnancy, or hypersensitivity risks;
• packaging and child-resistant closure deficiencies;
• manufacturing deviations affecting assay, dissolution, impurities, or stability;
• unapproved promotional claims.

The product should carry NSAID warnings addressing stomach bleeding and relevant cardiovascular and hypersensitivity risks. Labeling must also identify aspirin-sensitive asthma risk, pregnancy restrictions, interaction concerns, and the requirement to seek medical advice for persistent or worsening symptoms where applicable.[1,3]

What is the Orange Book status and patent position of Rugby All Day Relief?

Rugby All Day Relief is generally not expected to have an Orange Book patent estate comparable with a prescription NDA product. FDA’s Orange Book primarily identifies approved drug products and certain patent and exclusivity information associated with approved applications. A monograph-compliant OTC product normally competes without listed composition-of-matter or method-of-use patents.[4]

IP issue	Commercial assessment
Composition-of-matter patent	Expired for naproxen and naproxen sodium
Prescription exclusivity	None relevant to the established OTC product
Orange Book patent listing	Generally not expected for a monograph private-label product
Paragraph IV risk	Usually not applicable to monograph-based OTC substitution
Biosimilar risk	Not applicable
Formulation patents	Possible only for a specific novel dosage form or delivery system
Method-of-use patents	Limited commercial relevance for ordinary OTC analgesic indications
Trademark protection	Possible for the Rugby brand and product name
Manufacturing know-how	Potentially important but usually confidential rather than publicly enforceable

A private-label manufacturer may rely on an existing monograph-compliant formulation, an approved abbreviated application, or a contract-manufacturing arrangement. The absence of strong drug patents increases price competition and places greater value on supply reliability, cost control, packaging, retailer access, and quality performance.

When does Rugby All Day Relief lose exclusivity?

Rugby All Day Relief has no conventional branded-drug exclusivity period that determines generic entry. Naproxen sodium has been available for decades, and competing products can enter through the applicable OTC regulatory route.

The relevant commercial “exclusivity” is therefore channel-based:

• retailer shelf placement;
• institutional purchasing agreements;
• contract-manufacturing arrangements;
• preferred wholesaler status;
• temporary promotional pricing;
• retailer-specific packaging;
• private-label branding.

A supplier can protect customer relationships through service levels, quality metrics, validated manufacturing capacity, and packaging flexibility. Those defenses are commercial rather than patent-based.

Which companies challenge Rugby All Day Relief?

Competition comes from multiple categories rather than a single Paragraph IV challenger:

Competitor group	Examples
Branded OTC products	Aleve and related naproxen sodium products
Pharmacy private labels	CVS Health, Walgreens, Rite Aid, supermarket pharmacy brands
Mass retail private labels	Walmart, Target, Costco and comparable retailers
Generic pharmaceutical suppliers	Perrigo, Dr. Reddy’s, Teva, Amneal, and other OTC manufacturers
E-commerce brands	Marketplace and direct-to-consumer private-label suppliers
Therapeutic substitutes	Acetaminophen and ibuprofen products

The principal competitive pressure is price. Secondary pressure comes from dose-form convenience, package count, delivery format, retailer margin, and product availability.

What licensing and manufacturing opportunities exist?

Licensing opportunities are strongest where a manufacturer controls a differentiated dosage form, a low-cost compression process, or a validated high-throughput supply chain. Potential transactions include:

• private-label supply agreements with national retailers;
• contract manufacturing for pharmacy and club-store brands;
• co-development of easy-swallow or rapid-disintegration tablets;
• regional distribution rights;
• packaging and repackaging licenses;
• supply agreements for institutional and government purchasers.

A conventional 220 mg tablet is unlikely to support substantial royalty economics based solely on active-ingredient IP. Deal value would instead depend on manufacturing cost, regulatory readiness, capacity reservation, packaging assets, and customer access.

What generic launch risks exist for Rugby All Day Relief?

Generic launch risk is structurally high because entry barriers are low. A competing manufacturer can often match the product with standard excipients and ordinary tablet equipment.

The main barriers are:

1. FDA-compliant labeling and regulatory documentation.
2. Demonstrated dissolution, assay, content uniformity, and stability.
3. Reliable naproxen sodium API supply.
4. Adequate control of impurities and degradation products.
5. Retailer qualification and packaging compliance.
6. Child-resistant closure and tamper-evident packaging execution.
7. Capacity to support large, low-margin orders.
8. Product liability and NSAID quality systems.

Supply continuity can create a stronger commercial moat than formulation IP. A supplier that can maintain fill rates during retailer promotions may win contracts even with a chemically conventional product.

How strong is the Rugby All Day Relief patent estate?

The patent estate is weak as a standalone protection strategy because the product relies on an established OTC active ingredient and a conventional dosage form. The defensible assets are more likely to be:

• Rugby trademarks and trade dress;
• confidential manufacturing parameters;
• supplier qualification data;
• stability data;
• packaging configurations;
• retailer contracts;
• quality and compliance systems.

A novel delivery system, controlled-release formulation, or clinically differentiated combination could support new patent filings. Such protection would attach to the specific formulation or delivery technology, not to ordinary naproxen sodium tablets.

What commercial opportunities are most attractive?

The highest-probability opportunities are low-complexity extensions:

1. Value packs with optimized tablet counts and lower packaging cost.
2. Blister formats for travel and institutional use.
3. Easy-swallow film-coated caplets.
4. Retailer-specific private-label versions.
5. E-commerce multipacks with tamper-evident packaging.
6. Contract manufacturing for regional pharmacy chains.
7. International versions aligned with local OTC analgesic rules.

Premium liquid-filled or rapidly disintegrating products may generate higher gross margins but require greater investment in equipment, stability, taste, packaging, and regulatory support.

Key Takeaways

• Rugby All Day Relief is generally a naproxen sodium 220 mg OTC analgesic product.
• Its commercial value is based on private-label distribution and manufacturing efficiency, not active-ingredient patent exclusivity.
• The best excipient strategy is a conventional, scalable tablet platform with controlled lubrication, rapid disintegration, robust compression, and a protective film coat.
• Formulation differentiation is possible through caplets, rapid-disintegration formats, liquid-filled capsules, and blister packaging.
• Paragraph IV litigation and biosimilar competition are not central risks.
• The main threats are low-cost generic substitution, retailer bargaining power, supply disruption, and labeling or quality failures.
• The strongest commercial opportunities are retailer contracts, contract manufacturing, packaging differentiation, and reliable high-volume supply.

FAQs

Does Rugby All Day Relief contain ibuprofen?

No. Rugby All Day Relief is generally identified with naproxen sodium as the active ingredient. Ibuprofen is a different NSAID and should not be treated as an equivalent ingredient.

Can Rugby All Day Relief be reformulated with fewer excipients?

Yes, but reducing excipients can affect powder flow, tablet strength, dissolution, friability, coating performance, and stability. A lower-excipient formulation requires comparative quality and performance testing.

Is naproxen sodium suitable for a chewable tablet?

It can be formulated as a chewable product, but taste masking, mouthfeel, sweetener selection, and local irritation require focused development. The formulation would also need labeling and stability review under the applicable OTC framework.

Can a manufacturer patent a new Rugby All Day Relief formulation?

A manufacturer may seek patent protection for a genuinely novel formulation, delivery system, manufacturing process, or stability-enhancing composition. Ordinary use of established tablet excipients is unlikely to provide strong patent protection.

What is the most defensible commercial advantage for this product?

The most defensible advantage is a combination of reliable supply, low manufacturing cost, retailer access, compliant packaging, and a stable, consumer-friendly tablet. Those advantages are more important than conventional formulation patents for an established OTC naproxen sodium product.

References

1. U.S. Food and Drug Administration. (2023). Drug facts label requirements for over-the-counter analgesic products. FDA.

2. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

3. U.S. Food and Drug Administration. (2024). OTC monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.